logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
С

С. В. Орлов

Institute of Experimental Medicine
H指数:34
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
BREAST CANCER RESEARCH AND TREATMENT
IF3
2023-10-181
OA
Sokolenko, Anna P.; Bakaeva, Elvina Kh.; Venina, Aigul R.; Kuligina, Ekaterina Sh.; Romanko, Alexandr A.; Aleksakhina, Svetlana N.; Belysheva, Yana V.; Belogubova, Evgeniya V.; Stepanov, Ilya A.; Zaitseva, Olga A.; Yatsuk, Olga S.; Togo, Alexandr V.; Khamgokov, Zaur M.; Kadyrova, Azinat O.; Pirmagomedov, Albert Sh.; Bolieva, Marina B.; Epkhiev, Alexandr A.; Tsutsaev, Aslan K.; Chakhieva, Madina D.; Khabrieva, Khalimat M.; Khabriev, Idris M.; Murachuev, Mirza A.; Buttaeva, Bella N.; Baboshkina, Liliya S.; Bayramkulova, Fatima I.; Katchiev, Islam R.; Alieva, Lina Kh.; Raskin, Grigory A.; Orlov, Sergey V.; Khachmamuk, Zarema K.; Levonyan, Karine R.; Gichko, Dariya M.; Kirtbaya, Dmitriy V.; Degtyariov, Alexey M.; Sultanova, Luisa V.; Musayeva, Hedi S.; Belyaev, Alexey M.; Imyanitov, Evgeny N.
Osimertinib plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON

Osimertinib联合Savolitinib克服表皮生长因子受体突变、MET扩增非小细胞肺癌获得性MET介导的耐药: TATTON

CANCER DISCOVERY
IF33.3
2022-10-2070
OAAI
Hartmaier, Ryan J.; Markovets, Aleksandra A.; Ahn, Myung Ju; Sequist, Lecia, V; Han, Ji-Youn; Cho, Byoung Chul; Yu, Helena A.; Kim, Sang-We; Yang, James Chih-Hsin; Lee, Jong-Seok; Su, Wu-Chou; Kowalski, Dariusz M.; Orlov, Sergey; Ren, Song; Frewer, Paul; Ou, Xiaoling; Cross, Darren A. E.; Kurian, Nisha; Cantarini, Mireille; Jaenne, Pasi A.
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

北极: durvalumab联合或不联合tremelimumab作为转移性非小细胞肺癌的三线或晚期治疗

ANNALS OF ONCOLOGY
IF65.4
2020-05-01113
OAAI
Planchard, D.; Reinmuth, N.; Orlov, S.; Fischer, J. R.; Sugawara, S.; Mandziuk, S.; Marquez-Medina, D.; Novello, S.; Takeda, Y.; Soo, R.; Park, K.; McCleod, M.; Geater, S. L.; Powell, M.; May, R.; Scheuring, U.; Stockman, P.; Kowalski, D.
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

阿法替尼作为EGFR突变阳性非小细胞肺癌老年患者的一线治疗: LUX-Lung 3、LUX-Lung 6和LUX-Lung 7试验的亚组分析

CLINICAL LUNG CANCER
IF3.3
2018-07-0152
OAAI
Wu, Yi-Long; Sequist, Lecia V.; Tan, Eng-Huat; Geater, Sarayut L.; Orlov, Sergey; Zhang, Li; Lee, Ki Hyeong; Tsai, Chun-Ming; Kato, Terufumi; Barrios, Carlos H.; Schuler, Martin; Hirsh, Vera; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Boyer, Michael; Mok, Tony; Peil, Barbara; Marten, Angela; Yang, James Chih-Hsin; Paz-Ares, Luis; Park, Keunchil
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
IF55
2017-05-09287
OAAI
Janne, Pasi A.; van den Heuvel, Michel M.; Barlesi, Fabrice; Cobo, Manuel; Mazieres, Julien; Crino, Lucio; Orlov, Sergey; Blackhall, Fiona; Wolf, Juergen; Garrido, Pilar; Poltoratskiy, Artem; Mariani, Gabriella; Ghiorghiu, Dana; Kilgour, Elaine; Smith, Paul; Kohlmann, Alexander; Carlile, David J.; Lawrence, David; Bowen, Karin; Vansteenkiste, Johan
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
CLINICAL CANCER RESEARCH
IF10.2
2017-04-1376
OAAI
Ramalingam, Suresh S.; Blais, Normand; Mazieres, Julien; Reck, Martin; Jones, C. Michael; Juhasz, Erzsebet; Urban, Laszlo; Orlov, Sergey; Barlesi, Fabrice; Kio, Ebenezer; Keiholz, Ulrich; Qin, Qin; Qian, Jiang; Nickner, Caroline; Dziubinski, Juliann; Xiong, Hao; Ansell, Peter; McKee, Mark; Giranda, Vincent; Gorbunova, Vera
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

一线色瑞替尼与铂类化疗治疗晚期ALK重排非小细胞肺癌 (ASCEND-4): 一项随机、开放标签、3期研究

LANCET
IF88.5
2017-03-01930
PREAI
Soria, Jean-Charles; Tan, Daniel S. W.; Chiari, Rita; Wu, Yi-Long; Paz-Ares, Luis; Wolf, Juergen; Geater, Sarayut L.; Orlov, Sergey; Cortinovis, Diego; Yu, Chong-Jen; Hochmair, Maximillian; Cortot, Alexis B.; Tsai, Chun-Ming; Moro-Sibilot, Denis; Campelo, Rosario G.; McCulloch, Tracey; Sen, Paramita; Dugan, Margaret; Pantano, Serafino; Branle, Fabrice; Massacesi, Cristian; de Castro, Gilberto, Jr.
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

每三周向晚期实体瘤恶性肿瘤患者服用肽酶增强烷化剂melflufen的首次人体I/IIa期临床研究

INVESTIGATIONAL NEW DRUGS
IF2.7
2015-11-1028
PREAI
Berglund, Ake; Ullen, Anders; Lisyanskaya, Alla; Orlov, Sergey; Hagberg, Hans; Tholander, Bengt; Lewensohn, Rolf; Nygren, Peter; Spira, Jack; Harmenberg, Johan; Jerling, Markus; Alvfors, Carina; Ringbom, Magnus; Nordstrom, Eva; Soderlind, Karin; Gullbo, Joachim
Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy
EUROPEAN JOURNAL OF CANCER
IF7.1
2015-09-010
PREAI
Garon, E. B.; Scagliotti, G. V.; Gautschi, O.; Reck, M.; Thomas, M.; Docampo, L. I.; Kalofonos, H.; Kim, J. H.; Gans, S.; Brustugun, O. T.; Orlov, S. V.; Ferry, D.; Melemed, A.; Carter, G. C.; Zimmermann, A. H.; Treat, J. A.; Alexandris, E.; Lee, P.; Socinski, M. A.; Perol, M.
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
EUROPEAN JOURNAL OF CANCER
IF7.1
2015-02-0152
OAAI
Novello, Silvia; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Sergey; Krzakowski, Maciej; von Pawel, Joachim; Gottfried, Maya; Bondarenko, Igor; Liao, Meilin; Barrueco, Jose; Gaschler-Markefski, Birgit; Griebsch, Ingolf; Palmer, Michael; Reck, Martin
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Ramucirumab联合多西他赛与安慰剂联合多西他赛用于铂类治疗 (REVEL) 疾病进展后的IV期非小细胞肺癌的二线治疗: 一项多中心，双盲，随机3期试验

LANCET
IF88.5
2014-08-011.0K
PREAI
Garon, Edward B.; Ciuleanu, Tudor-Eliade; Arrieta, Oscar; Prabhash, Kumar; Syrigos, Konstantinos N.; Goksel, Tuncay; Park, Keunchil; Gorbunova, Vera; Dario Kowalyszyn, Ruben; Pikiel, Joanna; Czyzewicz, Grzegorz; Orlov, Sergey V.; Lewanski, Conrad R.; Thomas, Michael; Bidoli, Paolo; Dakhil, Shaker; Gans, Steven; Kim, Joo-Hang; Grigorescu, Alexandru; Karaseva, Nina; Reck, Martin; Cappuzzo, Federico; Alexandris, Ekaterine; Sashegyi, Andreas; Yurasov, Sergey; Perol, Maurice

研究方向

暂未获取到该数据
Y
Yi‐Long Wu
H 指数:135论文数:2,242被引数:11.2万
S
Sarayut Lucien Geater
H 指数:34论文数:146被引数:2.1万
M
Martin Reck
H 指数:88论文数:630被引数:5.3万
L
Luis Paz‐Ares
H 指数:116论文数:1,393被引数:9.4万
S
Silvia Novello
H 指数:87论文数:1,020被引数:4.8万
E
Evgeny N. Imyanitov
H 指数:39论文数:503被引数:6,421
N
Nikolai V. Ivanov
H 指数:17论文数:116被引数:1,337
M
Martin Reck
H 指数:79论文数:639被引数:5.9万
С
С. М. Баринов
H 指数:24论文数:263被引数:2,433
V
V.Ja. Shevchenko
H 指数:5论文数:11被引数:68